经口机器人手术治疗HPV阴性口咽癌的肿瘤学结局
中位随访30.6个月,3年总生存率、局部区域控制率和无病生存率分别为85.5%、84.4%和73.6%,围手术期死亡率1.8%,出血发生率3.6%。结论认为该术式可获得鼓舞人心的肿瘤学结局且并发症少见。
要点
- HPV阴性口咽癌经口机器人手术后3年总生存率达85.5%。
- 3年局部区域控制率84.4%,无病生存率73.6%。
- 围手术期死亡率1.8%,长期胃造瘘率5.4%,无气管造瘘。
核心结论
- 对可手术切除的HPV阴性口咽鳞状细胞癌,经口机器人手术可获得鼓舞人心的肿瘤学结局且并发症少见。
主要发现
- 3年总生存率为85.5%,3年局部区域控制率为84.4%,3年无病生存率为73.6%,中位随访30.6个月(四分位距18.4-66.6)。
- 18例(32.1%)接受辅助放疗,20例(39.3%)接受辅助放化疗。
- 围手术期死亡1例(1.8%),出血2例(3.6%),长期胃造瘘率5.4%,气管造瘘率0.0%。
临床怎么用
- 对于可手术切除的HPV阴性口咽鳞状细胞癌,经口机器人手术可作为获得较好肿瘤学控制且并发症较少的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) continue to experience disappointing outcomes following chemoradiotherapy (CRT) and appreciable morbidity following historical surgical approaches. We aimed to investigate the oncologic outcomes and perioperative morbidity of a transoral robotic surgery (TORS) approach to surgically resectable HPV-negative OPSCC. METHODS: Retrospective analysis HPV-negative OPSCC patients who underwent TORS, neck dissection and pathology-guided adjuvant therapy (2005-2017). RESULTS: Fifty-six patients (91.1% stage III/IV) were included. Three-year overall survival, locoregional control, and disease-free survival were 85.5%, 84.4%, and 73.6%, respectively (median follow-up 30.6 months, interquartile range 18.4-66.6). Eighteen (32.1%) patients underwent adjuvant radiotherapy and 20 (39.3%) underwent adjuvant CRT. Perioperative mortality occurred in one (1.8%) patient and hemorrhage occurred in two (3.6%) patients. Long-term gastrostomy and tracheostomy rates were 5.4% and 0.0%, respectively. CONCLUSION: The TORS approach for resectable HPV-negative OPSCC can achieve encouraging oncologic outcomes with infrequent morbidity.
引用
- Parhar HS, Weinstein GS, O'Malley BW, et al. Oncologic outcomes of transoral robotic surgery for HPV-negative oropharyngeal carcinomas. Head Neck. 2021. PMID: 34101290. doi:10.1002/hed.26776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。